嘉和生物-B(06998)与TRC 2004, INC.订立GB261许可协议

智通财经网08-05

智通财经APP讯，嘉和生物-B(06998)公布，该集团于2024年8月2日与TRC 2004, Inc. (被许可人)(一家由Two River, LLC(Two River)及Third Rock Ventures在美利坚合众国德拉瓦州共同创立的公司)订立许可协议以及股权协议。根据许可协议，该集团已同意(其中包括)授予被许可人全球独家许可(不包括中国大陆、中国香港、中国澳门及中国台湾)，以...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2457775092?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-08-05 07:07","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2457775092","market":"hk","top_or_hot":-1,"title":"嘉和生物-B(06998)与TRC 2004, INC.订立GB261许可协议","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，嘉和生物-B(06998)公布，该集团于2024年8月2日与TRC 2004, Inc. (被许可人)(一家由Two River, LLC(Two  River)及Third Rock  Ventures在美利坚合众国德拉瓦州共同创立的公司)订立许可协议以及股权协议。根据许可协议，该集团已同意(其中包括)授予被许可人全球独家许可(不包括中国大陆、中国香港、中国澳门及中国台湾)，以...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1159722.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>嘉和生物-B(06998)与TRC 2004, INC.订立GB261许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n嘉和生物-B(06998)与TRC 2004, INC.订立GB261许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-05 07:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1159722.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，嘉和生物-B(06998)公布，该集团于2024年8月2日与TRC 2004, Inc. (被许可人)(一家由Two River, LLC(Two  River)及Third Rock  Ventures在美利坚合众国德拉瓦州共同创立的公司)订立许可协议以及股权协议。根据许可协议，该集团已同意(其中包括)授予被许可人全球独家许可(不包括中国大陆、中国香港、中国澳门及中国台湾)，以...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1159722.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1159722.html","article_id":"2457775092","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457775092","pubTimestamp":1722812841,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"嘉和生物-B(06998)公布，该集团于2024年8月2日与TRC 2004, I...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK4193":"多样化房地产活动","TRC":"Tejon Ranch Co","BK1583":"高瓴概念","06998":"嘉和生物-B","BK1161":"生物科技"},"translate_title":"Jiahe Bio-B (06998) enters into GB261 license agreement with TRC 2004, INC.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":1,"TRC":1},"content_text":"智通财经APP讯，嘉和生物-B(06998)公布，该集团于2024年8月2日与TRC 2004, Inc. (被许可人)(一家由Two River, LLC(Two  River)及Third Rock  Ventures在美利坚合众国德拉瓦州共同创立的公司)订立许可协议以及股权协议。根据许可协议，该集团已同意(其中包括)授予被许可人全球独家许可(不包括中国大陆、中国香港、中国澳门及中国台湾)，以开发、使用、制造、商业化及以其他方式利用GB261。根据许可协议和股权协议的条款，作为许可的代价，该集团将获得被许可人数量可观的股权;数千万美元的首付款;高达4.43亿美元的里程碑付款;及占净销售额个位数到双位数百分比的分层特许权使用费。据悉，GB261是一种新型差异化CD20/CD3双特异性T细胞接合剂(TCE)，具有超低CD3  结合亲和力和完整的Fc功能(ADCC和CDC)。公司先前已在中国和澳洲成功完成针对B-NHL(DLBCL和FL)进行的Ph1/2期多中心研究。结果显示出非常优越的安全性和有效性。例如，与其他同类化合物相比，GB261已被证明可显著减少细胞激素释放(CRS)。GB261的特性使其成为一种非常有前景的B细胞耗竭剂，其适应症潜力超出肿瘤学范围，也适用于患者中有大量未满足医疗需求的各种免疫学和自体免疫适应症。与被许可人的合作将主要集中在探索GB261在自体免疫疾病方面的潜力。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457775092"}